July • August 2003 - Ontario College of Pharmacists

HEALTH CANADA
Advisories & Notices
DATE
June 9 / 03
June 6 / 03
June 4 / 03
May 28 / 03
May 27 / 03
May 23 / 03
May 9 / 03
May 8 / 03
April 29 / 03
April 28 / 03
April 14 & 17 / 03
April 10 / 03
April 2 / 03
April 1 / 03
March 18 /03
March 12 / 03
March 5 &
February 28 / 03
February 28 / 03
February 19 / 03
February 17 / 03
February 17 / 03
February 13 / 03
January 30 / 03
TYPE
Advisory – Health Canada reminds Canadians of the Dangers of Ephedra / ephedrine products
Advisory – Health Canada is advising Canadians not to use Empowerplus. Also known as EM Power+ and EM
Power sold by Truehope Nutritional Support Limited (also known as Synergy)
Insulin Products in Canada – an update from Health Canada
Important Safety Information on Estrogen Plus Progestin (PremplusTablets) – Wyeth Pharmaceuticals
Warning – Health Canada warns the public not to use Hua Fo / VIGOR-MAX
tablets, a Chinese herbal product that contains tadalafil. Inappropriate use of tadalafilcould cause severe
adverse reactions
Important Medical Devices Safety Advisory to users of Siemens Servo 300 / 300A Ventilators – Siemens
Canada Limited
Public Advisory – Bronchial Problems Associated with Rapamune® (sirolimus) – Wyeth Pharmaceuticals
Advisory – Health Canada advises against the use of SEAVITE products containing iodine
Advisory – Health Canada is advising Canadians to be wary of products with claims concerning the
prevention or treatment of SARS
Advisory – Health Canada is advising Canadians of a dangerous interaction between diathermy therapy and
implanted metallic leads
Important Safety Information & Public Advisory Regarding Permax ® (pergolide mesylate) and Cardiac
Valvulopathy – Eli Lilly Canada Inc. and Draxis Health Inc.
Important Safety Information & Public Advisory About DIANE ® - 35 and the Risk of Venous
Thromboembolism – Berlex Canada Inc.
Notice to Hospitals - Important Safety Information Regarding Diathermy Therepy – Health Canada
Important Dosing Clarification for Fragmin® (dalteparin sodium injection) – Pharmacia Canada Inc.
Advisory on Diethylstilbestrol (DES) and the Risk of Genital and Obstetrical Complications – Health Canada
Important Safety Information Regarding Ethyol (Amifostine) and Severe Cutaneous Reactions – Health
Canada
New Safety Information Associated with the Use of Zoloft® (sertraline hydrochloride) in Patients taking
Pimozide (Contraindication) – Pfizer Canada Inc.
Advisory – Health Canada reports back to public on safety profile of Meridia ® (sibutramine)
Warning Regarding Rapamune® (sirolimus) and Bronchial Anastomotic Dehiscence including Fatal Cases –
Wyeth Pharmaceuticals
Notice to Hospitals – Cochlear Implant Recipients may be a Greater Risk for Meningitis – Information Update,
Health Products and Food Branch
Letter to Healthcare Professionals Regarding Synagis® (pavlivizumab) – Abbott Laboratories Limited
Advisory – Health Canada is advising Canadians about the safe use of products containing Acetaminophen
New Contraindication Regarding Ergotamine and Dihydroergotamine – containing drugs: Risk of Cerebral
and/or Peripheral Ischemia – Novartis Pharmaceuticals Canada Inc.
For complete information and electronic mailing of the Health Canada Advisories / Warnings /Notices,
subscribe online at: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/
Pharmacy Connection July • August 2003 23